Skip to main content

Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.

The on-demand webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CTP-543 in adults with alopecia areata, a serious autoimmune dermatological condition. The Company is also evaluating the use of CTP-543 in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.48
+3.44 (1.61%)
AAPL  262.24
+9.95 (3.94%)
AMD  240.56
+7.48 (3.21%)
BAC  52.04
+0.76 (1.48%)
GOOG  257.02
+3.23 (1.27%)
META  732.17
+15.26 (2.13%)
MSFT  516.79
+3.21 (0.63%)
NVDA  182.64
-0.58 (-0.32%)
ORCL  277.18
-14.13 (-4.85%)
TSLA  447.43
+8.12 (1.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.